Certara, Inc. · NASDAQ:CERT
Certara — Technical Presentation (May 2014)
41 slides from Certara's technical presentation, May 1, 2014
Slide 1: Accelerating Decision-making Related to Cardiac Safety
Accelerating Decision-making Related to Cardiac Safety Helen Moore, PhD May 1, 2014 1
Slide 2: Today's Presenter
Today’s Presenter • Helen Moore, PhD – Joined Certara (then Pharsight) in 2009 – Modeling and simulation consultant – Trainer of modeling theory and software – Previous positions at Genentech, the American Institute of Mathematics, Stanford University, Bowdoin College – Expertise in population PK/PD
Slide 3: Agenda
Agenda • Background and Regulatory Expectations • Overview of Phoenix QT+ for Cardiac Safety Analysis • Streamlined QT Analysis Example in Phoenix QT+ • Q&A © Copyright 2014 Certara, L.P. All rights reserved. 3
Slide 4: Background: Why the Concern and Why QT Analysis?
Background: Why the Concern and Why QT Analysis? • Drug-induced QT interval prolongation is Anthony Atkielski / Wikimedia Commons / Public Domain a biomarker for torsades de pointes (TdP) • TdP is a heart arrythmia that can lead to sudden death Wikimedia Commons / Public Domain • QT prolongation has
Slide 5: Regulatory Expectations
Regulatory Expectations • Defines Thorough QT (TQT) Study • If positive, more intensive ECG monitoring is needed in later studies • Explains use of concentration-QTc modeling for better decision-making © Copyright 2014 Certara, L.P. All rights reserved. 5
Slide 6: Overview of Phoenix QT+
Overview of Phoenix QT+ © Copyright 2014 Certara, L.P. All rights reserved. 6
Slide 7: Phoenix QT+
Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data © Copyright 2014 Certara, L.P. All rights reserved. 7
Slide 8: Phoenix QT+
Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin © Copyright 2014 Certara, L.P. All rights reserved. 8
Slide 9: Phoenix QT+
Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies © Copyright 2014 Certa
Slide 10: Phoenix QT+
Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies • Can shorten time for
Slide 11: Phoenix QT+ Workflow Objects
Phoenix QT+ Workflow Objects Heart Rate Correction Data Processing QT Transformations Central Tendency Basic QT Analysis Outlier Analysis Exploratory Plots Concentration- QTc Modeling C-QTc © Copyright 2014 Certara, L.P. All rights reserved. 11
Slide 12: QT+ Workflow to Analyze Study Data
QT+ Workflow to Analyze Study Data Concentration-QTc Modeling © Copyright 2014 Certara, L.P. All rights reserved. 12
Slide 13: QT+ to Demonstrate Assay Sensitivity
QT+ to Demonstrate Assay Sensitivity Study demonstrates assay sensitivity © Copyright 2014 Certara, L.P. All rights reserved. 13
Slide 14: QT+ to Test for Positive TQT Study
QT+ to Test for Positive TQT Study Positive TQT study for NuDrug at 100 mg © Copyright 2014 Certara, L.P. All rights reserved. 14
Slide 15: QT+ to Model Concentration-QTc Relationship
QT+ to Model Concentration-QTc Relationship Treatment Group Source Concentration Time Prediction 5% Prediction 50% Prediction 95% NuDrug 20 mg Cmax 0.92 2.50 1.26 1.93 2.63 NuDrug 100 mg Cmax 4.84 2.50 6.48 10.23 13.48 NuDrug User 0.75 2.50 1.01 1.59 2.15 NuDrug User 2.50 2.50 3.36 5.29 7.16 Upper 9
Slide 16: Streamlined QT+ Demo
Streamlined QT+ Demo © Copyright 2014 Certara, L.P. All rights reserved. 16
Slide 17: We Used Phoenix QT+ to Do the Following
We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay © Copyright 2014 Certara, L.P. All rights reserved. 17
Slide 18: We Used Phoenix QT+ to Do the Following
We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay • Test to see if a TQT study was positive © Copyright 2014 Certara, L.P. All rights reserved. 18
Slide 19: We Used Phoenix QT+ to Do the Following
We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay • Test to see if a TQT study was positive • Produce a table of outliers © Copyright 2014 Certara, L.P. All rights reserved. 19
Slide 20: We Used Phoenix QT+ to Do the Following
We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay • Test to see if a TQT study was positive • Produce a table of outliers • Perform concentration-QTc modeling © Copyright 2014 Certara, L.P. All rights reserved. 20
Slide 21: Recap: Phoenix QT+
Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data © Copyright 2014 Certara, L.P. All rights reserved. 21
Slide 22: Recap: Phoenix QT+
Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin © Copyright 2014 Certara, L.P. All rights reserved. 22
Slide 23: Recap: Phoenix QT+
Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies © Copyright 201
Slide 24: Recap: Phoenix QT+
Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies • Can shorten t
Slide 25: Recap: Phoenix QT+
Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies • Can shorten t
Slide 26: Q&A Session on Phoenix QT+ for Cardiac Safety
Q&A Session on Phoenix QT+ for Cardiac Safety © Copyright 2014 Certara, L.P. All rights reserved. 26
Slide 27: Contacts & Follow-Up: Thank you!
Contacts & Follow-Up: Thank you! For more information regarding today’s presentation, please contact: • Helen Moore, Senior Scientific Consultant • helen.moore@certara.com For more information on Certara’s products & services, please contact our sales group: Americas India Email: sales@certara.com E
Slide 28: Additional Slides for Viewers of Webinar
Additional Slides for Viewers of Webinar © Copyright 2014 Certara, L.P. All rights reserved.
Slide 29: Apply Different HR Correction Methods
Apply Different HR Correction Methods Select HR correction methods © Copyright 2014 Certara, L.P. All rights reserved. 29
Slide 30: Apply Statistical Methods to Evaluate
Apply Statistical Methods to Evaluate Select statistical evaluation methods © Copyright 2014 Certara, L.P. All rights reserved. 30
Slide 31: Summary Worksheet of Results
Summary Worksheet of Results Slopes closer to zero for QTcF than QTcP for almost all comparisons © Copyright 2014 Certara, L.P. All rights reserved. 31
Slide 32: QTc vs. RR Plots
QTc vs. RR Plots Slopes closer to zero for QTcF than QTcB, so select QTcF for further analysis © Copyright 2014 Certara, L.P. All rights reserved. 32
Slide 33: Baseline- & Placebo-Correct QTcF for Analysis
Baseline- & Placebo-Correct QTcF for Analysis © Copyright 2014 Certara, L.P. All rights reserved. 33
Slide 34: Central Tendency: ΔQTcF vs Time Plots
Central Tendency: ΔQTcF vs Time Plots Positive TQT study for NuDrug at 100 mg © Copyright 2014 Certara, L.P. All rights reserved. 34
Slide 35: Central Tendency Object: Assay Sensitivity
Central Tendency Object: Assay Sensitivity Study demonstrates assay sensitivity © Copyright 2014 Certara, L.P. All rights reserved. 35
Slide 36: Outlier Analysis: NuDrug only at 100mg
Outlier Analysis: NuDrug only at 100mg Default settings (all settings can be customized) © Copyright 2014 Certara, L.P. All rights reserved. 36
Slide 37: Exploratory Plots Object
Exploratory Plots Object • Mean ΔΔQTc vs. time overlay with mean Conc vs. Time • Individual and mean hysteresis plots • Scatterplots with linear regression line of Conc vs. QTc (ΔQTc, ΔΔQTc, PR, QRS, etc.) © Copyright 2014 Certara, L.P. All rights reserved. 37
Slide 38: C-QTc Object: Linear Model with Intercept
C-QTc Object: Linear Model with Intercept Theta Worksheet Goodness of Fit © Copyright 2014 Certara, L.P. All rights reserved. 38
Slide 39: C-QTc Object: Linear Model with Time-Intercept
C-QTc Object: Linear Model with Time-Intercept Theta Worksheet Better precision on slope and lower residual error Goodness of Fit No pattern in residual plots © Copyright 2014 Certara, L.P. All rights reserved. 39
Slide 40: C-QTc Prediction Uses Bootstrap Methodology
C-QTc Prediction Uses Bootstrap Methodology Enter concentrations for QTcF prediction from final model Enter the number of bootstrap replicates © Copyright 2014 Certara, L.P. All rights reserved. 40
Slide 41: C-QTc Prediction Summary Table and Plot
C-QTc Prediction Summary Table and Plot Treatment Group Source Concentration Time Prediction 5% Prediction 50% Prediction 95% NuDrug 20 mg Cmax 0.92 2.50 1.26 1.93 2.63 NuDrug 100 mg Cmax 4.84 2.50 6.48 10.23 13.48 NuDrug User 0.75 2.50 1.01 1.59 2.15 NuDrug User 2.50 2.50 3.36 5.29 7.16 Upper 95% C